Company intelligence / Profile preview

CivicaScript

Lehi, Utah, United Statescivicascript.com ↗

Ownership: Private
Development stage: Other

Overview

CivicaScript has demonstrated cost savings in real-world patient and payer studies with its generic abiraterone (prostate cancer), and is expanding into biosimilars with exclusive, low-cost distribution (notably ustekinumab-aauz biosimilar for chronic inflammatory conditions)

Therapeutic areas: EndocrinologyDermatologyRheumatologyGastroenterologyOncology
Modalities: Small moleculeMonoclonal antibodyBiosimilarBiologic
Industry: Biotech

Partnerships

Blue Cross Blue Shield Association (BCBSA) and 18 Blue Cross Blue Shield plansFresenius Kabi (manufacturer of ustekinumab-aauz biosimilar)Catalent (CDMO manufacturing partner for oral solids)Hikma Pharmaceuticals (manufacturing abiraterone acetate)GeneSys Biologics (co-development/commercial insulin biosimilars)SortPak (packaging and compliance partner)Navitus and EmsanaRx (PBM partnerships)

Beyond the preview

Go deeper on CivicaScript.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CivicaScript.